Connect Biopharma Holdings Ltd ADR (CNTB)

Overview News Price History Option Chain Discussions Forecast

Connect Biopharma Holdings Ltd ADR stock is currently priced at $1.35, with a 24-hour trading volume of 50,898. It has seen a -12.34% decreased in the last 24 hours and a +5.47% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.52 pivot point. If it approaches the $1.34 support level, significant changes may occur.

Connect Biopharma Holdings Ltd ADR Stock (CNTB) Financials Data

Connect Biopharma Holdings Ltd ADR (CNTB) Net Income 2024

CNTB net income (TTM) was -$85.88 million for the quarter ending June 30, 2023, a +65.93% increase year-over-year.

Connect Biopharma Holdings Ltd ADR (CNTB) Cash Flow 2024

CNTB recorded a free cash flow (TTM) of -$80.96 million for the quarter ending June 30, 2023, a -23.27% decrease year-over-year.

Connect Biopharma Holdings Ltd ADR (CNTB) Earnings per Share 2024

CNTB earnings per share (TTM) was -$1.5686 for the quarter ending June 30, 2023, a +69.12% growth year-over-year.

Connect Biopharma Holdings Ltd ADR Stock (CNTB) Latest News

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

GlobeNewswire Inc.

Are Medical Stocks Lagging Bausch Health (BHC) This Year?

Zacks Investment Research

Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Benzinga

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

GlobeNewswire Inc.

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

GlobeNewswire Inc.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with AD. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.